Tatva Chintan Pharma Chem: June ’22 Results Update
Moneylife Digital Team 01 August 2022
Tatva Chintan Pharma Chem (Tatva) reported poor numbers, yet again. Revenue declined by 17% y-o-y (year-on-year) and 10% q-o-q (quarter-on-quarter) to Rs88 crore. This was on the back of drastic drop in SDA (structure directing agent) sales. SDA sales crashed by 89% y-o-y, due to chip shortage, geo-political situation in Europe and lock-down in China because of COVID-19. The management...
Archived Premium Content
This article is outside your subscription period. You can buy this article individually.
SINGLE ARTICLE
Rs 50-Rs 100 + GST
Access will be given ONLY to this article.
 
Get access to complete archives
Rs 5000 + GST
 
 
Already a subscriber ? Log in
Free Helpline
Legal Credit
Feedback